Study of toxicity effect of pegylated nanoliposomal artemisinin on breast cancer cell line

Indian Journal of Clinical Biochemistry

Volumn 28, Issue 4, 2013, Pages 410-412

  Dadgar, Neda ^a   Alavi, Seyed Ebrahim ^a,b   Esfahani, Maedeh Koohi Moftakhari ^a,b   Akbarzadeh, Azim ^b  

^a ISLAMIC AZAD UNIVERSITY   (Iran)

^b PASTEUR INSTITUTE OF IRAN   (Iran)

Author keywords

Artemisinin; Breast cancer; Nanoliposome; Pegylation

Indexed keywords

ARTEMISININ; LIPOSOME; MACROGOL 2000; NANOLIPOSOME; NANOPARTICLE; PHOSPHATIDYLCHOLINE; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL STRAIN MCF 7; DRUG CYTOTOXICITY; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG SAFETY; DRUG STABILITY; IC 50; NANOENCAPSULATION; PARTICLE SIZE;

EID: 84885045770     PISSN: 09701915     EISSN: 09740422     Source Type: Journal    
DOI: 10.1007/s12291-013-0306-3     Document Type: Article

References (15)

1. Yatuv R, Robinson M, Dayan-Tarshish I, Baru M. The use of pegylated liposomes in the development of drug delivery applications for the treatment of hemophilia. Int J Nanomed. 2010;5:581-91.
2. Dass CR, Choong PF. Carrier-mediated delivery of peptidic drugs for cancer therapy. Peptides. 2006;27:3020-8.
3. Xiang L, Yan Z, Wang G, Liu W, Tang K, Liao Z. Relative expression of genes involved in artemisinin biosynthesis and artemisinin accumulation in different tissues of artemisia annua. Zhongguo Zhong Yao Za Zhi. 2012;37:1169-73.
4. Latif N, Bachhawat BK. Liposomes in immunology. J Biosci. 1984;6:491-502.
5. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2:751-60.
6. Lai H, Singh NP. Oral artemisinin prevents and delays the development of 7,12-dimethylbenz[a]anthracene (DMBA)-induced breast cancer in the rat. Cancer Lett. 2006;231:43-8.
7. Guo J, Bourre L, Soden DM, O'Sullivan GC, O'Driscoll C. Can non-viral technologies knockdown the barriers to siRNA delivery and achieve the next generation of cancer therapeutics? Biotechnol Adv. 2011;29:402-17.
8. Maurer N, Fenske DB, Cullis PR. Developments in liposomal drug delivery systems. Expert Opin Biol Ther. 2001;1:923-47.
9. Buzea C, Pacheco II, Robbie K. Nanomaterials and nanoparticles: sources and toxicity. Biointerphases. 2007;2:17-71.
10. Gabizon A, Papahadjopoulos D. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci USA. 1988;85:6949-53.
11. Nakase I, Lai H, Singh NP, Sasaki T. Anticancer properties of artemisinin derivatives and their targeted delivery by transferrin conjugation. Int J Pharm. 2008;354:28-33.
12. Veronese FM. Peptide and protein PEGylation: a review of problems and solutions. Biomaterials. 2001;22:405-17.
13. Kawai F. Microbial degradation of polyethers. Appl Microbiol Biotechnol. 2002;58:30-8.
14. Ryan SM, Mantovani G, Wang X, Haddleton DM, Brayden DJ. Advances in PEGylation of important biotech molecules: delivery aspects. Expert Opin Drug Deliv. 2008;5:371-83.
15. Woodley JF. Liposomes for oral administration of drugs. Crit Rev Ther Drug Carrier Syst. 1985;2:1-18.